Thus, these results suggest that adjunctive ZOL/IL-2 therapy could enhance immune responses of anti-TB Vγ2Vδ2 T, CD4 + Th1 and CD8 + T effector populations, and led to lower MDR-TB bacterial burdens with favourable clinical outcome as body weight gains. This evidence concerns the gene IL2 and tuberculosis.